ridaforolimus Report issue

Small molecule Experimental
AACT ChEMBL Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Ridaforolimus is an investigational targeted and small-molecule inhibitor of the protein mTOR, a protein that acts as a central regulator of protein synthesis, cell proliferation, cell cycle progression and cell survival, integrating signals from proteins, such as PI3K, AKT and PTEN known to be important to malignancy. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis.   Wikipedia

Chemistry

  • SMILES: CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OP(=O)(C)C
  • InChIKey: BUROJSBIWGDYCN-GAUTUEMISA-N
  • Mol. Mass: 990.22
  • ALogP: 7.74
  • ChEMBL Molecule:
    ridaforolimus  
More Chemistry

Pharmacology

Alternative names

ap23573 | ap-23573 | deforolimus | jenzyl | mk8669 | mk 8669 | mk-8669 | ridaforolimus

Organizations (16)

Research & Development (16)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (22)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (22)


 

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Endometrial Neoplasms (Phase 2)

Glioblastoma (Phase 1)

Glioma (Phase 1)

Gliosarcoma (Phase 1)

Healthy Volunteers (Phase 1)

Hematologic Neoplasms (Phase 2)

Hepatic Insufficiency (Phase 1)

Leiomyosarcoma (Phase 2)

Leukemia (Phase 2)

Liposarcoma (Phase 2)

Lymphoma (Phase 2)

Multiple Myeloma (Phase 1)

Myelodysplastic Syndromes (Phase 2)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 2)

Osteosarcoma (Phase 2)

Ovarian Neoplasms (Phase 1)

Primary Myelofibrosis (Phase 2)

Prostatic Neoplasms (Phase 2)

Sarcoma (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 37
  • # of Trial Organizations: 16

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue